Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Acumen Pharmaceuticals, Inc. ABOS

Set alert

Price alert · ABOS

All alert types
0.24 USD +0.03 +14.09%

At close · Nov 2

0.22 -0.02 -8.22%

After hours · Nov 2, 7:59 PM ET

Bid
0.23 × 2
Ask
0.24 × 2
0.198 Day range 0.2668
0.21 52-week range 3.37
YTD
-88.64%
1 year
-89.15%
Open
0.2006
Prev close
0.2101
Mkt cap
17.34M
Vol
33.71M
Avg vol
1.56M
EPS
-1.55
P/E
0.00
Div yield
0.00%
More statistics
Low
0.198
High
0.2668
Forward P/E
-1.17
Beta
0.04
Short ratio
6.61
Inst. own
78.46%
Dividend
0.00
Ex-div date
Earnings
Aug 13, 2024
50-d avg
2.48
200-d avg
2.89
1y target
10.80

5D chart

Chart tools
Interval
1m5m15m30m

Signals (91)
NameTimeAgo
MACD: Sell SignalNov 2, 3:35 PM11 hours ago
SMA: BearishNov 2, 3:25 PM11 hours ago
SMA: BullishNov 2, 3:20 PM12 hours ago
SMA: BearishNov 2, 3:15 PM12 hours ago
MACD: Buy SignalNov 2, 3:05 PM12 hours ago
SMA: BullishNov 2, 3:00 PM12 hours ago
MACD: Sell SignalNov 2, 2:20 PM13 hours ago
SMA: BearishNov 2, 2:15 PM13 hours ago
MACD: Buy SignalNov 2, 2:15 PM13 hours ago
SMA: BullishNov 2, 2:05 PM13 hours ago
SMA: BearishNov 2, 2:00 PM13 hours ago
SMA: BullishNov 2, 1:55 PM13 hours ago
SMA: BearishNov 2, 1:50 PM13 hours ago
SMA: BullishNov 2, 1:45 PM13 hours ago
SMA: BearishNov 2, 12:40 PM14 hours ago
SMA: BearishNov 2, 12:25 PM14 hours ago
MACD: Sell SignalNov 2, 12:25 PM14 hours ago
SMA: BullishNov 2, 11:50 AM15 hours ago
SMA: BearishNov 2, 11:45 AM15 hours ago
SMA: BullishNov 2, 11:10 AM16 hours ago

Newest 20 of 91.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 10.80 +4405.6% upside
Target (low)
6.00
Target (mean)
10.80
Target (high)
15.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy5
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 6
  • 1 month ago 6
  • 2 months ago 6

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ABOS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.36582-0.42 – -0.30745-0.29-26.1%00.0%3
Next quarter0.000.00 – 0.000.000.0%00.0%0
Current year-1.32-1.51 – -0.99693-1.08-22.4%00.0%3
Next year-1.53-1.69 – -1.34-1.32-15.5%00.0%3

Upgrades and downgrades

The latest rating changes

ABOS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 3, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 15, 2024UBSMaintainedBuyBuy
Aug 14, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jul 25, 2024CitigroupInitiated—Buy
May 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 31, 2024UBSMaintainedBuyBuy
Mar 27, 2024HC Wainwright & Co.MaintainedBuyBuy
Dec 12, 2023Deutsche BankInitiated—Buy
Aug 9, 2023Credit SuisseReiteratedOutperformOutperform
Aug 9, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jul 17, 2023Cantor FitzgeraldReiteratedOverweightOverweight
Jul 17, 2023HC Wainwright & Co.ReiteratedBuyBuy
May 18, 2023Cantor FitzgeraldInitiated—Overweight
Mar 28, 2023Credit SuisseMaintained—Outperform
Mar 28, 2023HC Wainwright & Co.Reiterated—Buy
Feb 2, 2023HC Wainwright & Co.Reiterated—Buy
Nov 15, 2022Credit SuisseMaintained—Outperform
Oct 5, 2022BTIGMaintained—Buy
Jul 15, 2022BTIGInitiated—Buy
Jun 30, 2022HC Wainwright & Co.Initiated—Buy
Mar 29, 2022Credit SuisseMaintained—Outperform
Jan 21, 2022B of A SecuritiesUpgradeNeutralBuy
Jul 26, 2021UBSInitiated—Buy
Jul 26, 2021B of A SecuritiesInitiated—Neutral
Jul 26, 2021Credit SuisseInitiated—Outperform
Jul 26, 2021StifelInitiated—Buy